Extract

Dear Editor, Chronic actinic dermatitis (CAD) is a rare, immunologically mediated photodermatosis characterized by dermatitis at a photo-exposed site in association with objective evidence of photosensitivity, predominantly to ultraviolet (UV) B light, but often also extending to UVA and visible wavelengths. It may arise on a background of a pre-existing dermatitis, such as atopic dermatitis (AD), and is commonly associated with concomitant allergic contact dermatitis (ACD).1 The aetiology of CAD is not fully understood but is likely to involve a delayed T-cell-mediated hypersensitivity to an unknown photoinduced allergen. The current management approach for CAD involves careful photoprotection, topical corticosteroids and calcineurin inhibitors, sometimes psoralen plus UVA or phototherapy if tolerated, or the use of immunosuppressants such as azathioprine, methotrexate, mycophenolate mofetil or ciclosporin. Dupilumab is a monoclonal antibody that inhibits signalling of interleukin (IL)-4 and IL-13 and is licensed for the management of moderate-to-severe AD, with high rates of efficacy. Our study aims to describe the clinical and objective phototesting outcomes to treatment with dupilumab in patients with AD and CAD.

You do not currently have access to this article.